Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they’ve often fallen short. New ...
SHANGHAI, April 10 (Reuters) - Amgen's lung cancer drug tarlatamab has won approval from China's National Medical Products Administration, its development and commercialisation partner BeOne Medicines ...
The U.S. Food and Drug Administration on Friday declined to approve Replimune's drug for advanced skin cancer, ...
For more than a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The ...
A cancer drug candidate that, rightly or wrongly, became a flashpoint at FDA, fails on a second try at approval.
Former Sen. Ben Sasse is taking Revolution Medicines' daraxonrasib, which has shown promise as a treatment for pancreatic ...
Morning Overview on MSN
Researchers find some cancer drugs work differently than their stated targets
As of spring 2026, a cancer drug that has spent years in clinical development as a Wnt/beta-catenin pathway blocker has been ...
Mutations in a protein called KRAS fuel some of the most lethal cancers. Designing drugs to disable KRAS has proved ...
On average, patients with platinum-resistant ovarian cancer only live for around one year to 18 months after diagnosis.
Former GOP Sen. Ben Sasse is opening up about living with what he describes as a “definite death sentence.” The 54-year-old ...
University of Mississippi research offers hope that cancer drug therapies packaged in 3D-printed carriers could deliver ...
A Paragould pharmacy owner says he has been unable to gain access to a restricted distribution program for a cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results